Neprilysin as a Biomarker: Challenges and Opportunities
Neprilysin (NEP) inhibition is a successful novel therapeutic approach in heart failure with reduced ejection fraction. Assessing individual NEP status might be important for gathering insights into mechanisms of disease and optimising individualised patient care. NEP is a zinc-dependent multisubstr...
Guardado en:
Autores principales: | Noemi Pavo, Suriya Prausmüller, Philipp E Bartko, Georg Goliasch, Martin Hülsmann |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e888015c1f514aef8dcdc4ce628d660b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway
por: Ferhat Dindaş, et al.
Publicado: (2021) -
Relevance of Neutrophil Neprilysin in Heart Failure
por: Suriya Prausmüller, et al.
Publicado: (2021) -
Cardiovascular clinical trials in Africa: opportunities and challenges
por: Marli Terblanche, et al.
Publicado: (2017) -
Big Data and Artificial Intelligence: Opportunities and Threats in Electrophysiology
por: Rutger R van de Leur, et al.
Publicado: (2020) -
New opportunities for reducing cardiovascular risk in the Russian Federation
por: O. D. Ostroumova, et al.
Publicado: (2020)